heartbeat medical

heartbeat-med.com →

-64%

est. 2Y upside i

HealthcareSeries A

Stage: early. Country: Germany

Rank

#1829

Sector

Digital Health

Est. Liquidity

~3Y

Data Quality

Data: Low

Heartbeat Medical operates in a growing digital health niche with a moderate competitive moat, evidenced by its CE-marked platform and deep integrations.

Last updated: March 10, 2026

Bull (15%)+300%

Heartbeat Medical expands its platform into new European markets and successfully partners with a major US healthcare system, significantly increasing its customer base and data moat. Revenue grows to $80M+ by 2028, justifying an $800M+ valuation (4x current) at 10x revenue, driven by strong adoption of its CE-marked RWE solutions.

Base (50%)+75%

Heartbeat Medical continues steady growth in its core European markets, maintaining its position against smaller competitors but facing increasing pressure from larger health tech players. Revenue reaches $45M-$50M by 2028, leading to an exit valuation of $350M (1.75x current) at a 7x-8x revenue multiple.

Bear (35%)-80%

Increased competition from incumbent EHR vendors and new entrants, coupled with slower-than-expected market adoption, limits growth and forces a down round or fire sale. Revenue stagnates around $25M, and a valuation of $40M (0.2x current) results in significant loss of common stock value due to liquidation preferences.

Est. time to liquidity~3.0 years

Preference Stack Risk

moderate

Investors hold $17M in liquidation preferences ahead of common stock, representing 8.5% of the estimated current valuation of $200M.

Dilution Risk

high

Significant dilution is expected from future funding rounds (likely Series B and C) before a potential liquidity event.

Secondary Liquidity

none

There is currently no active secondary market or tender offers for employee equity at this stage.

Questions to Ask at the Interview

Strategic questions based on heartbeat medical's data — designed to show you've done your homework.

1
“How is Heartbeat Medical strategically planning to defend its market position and differentiate its offerings against potential RWE solutions from dominant EHR vendors like Epic or Cerner, especially given their extensive existing hospital networks?”
2
“With an estimated current revenue of approximately $28M and a TAM weighted growth of ~10% YoY, what are the company's specific strategies to accelerate growth beyond the market average and secure a successful Series B funding round in the next 12-18 months?”
3
“Given the Series A funding in 2020 and the current stage of the company, what is the anticipated timeline for a Series B round, and what are the company's expectations regarding a potential liquidity event (e.g., acquisition, IPO) for employees holding equity over the next 2-4 years?”

Community

Valuation Sentiment

Our model estimates -64% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.